5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.

作者： Nina D. Wagner-Johnston , Jeff A. Sloan , Heshan Liu , Ann E. Kearns , Stephanie L. Hines

关键词: Randomized controlled trial 、 Aromatase 、 Bone density 、 Tamoxifen 、 Bone Density Conservation Agents 、 Medicine 、 Zoledronic acid 、 Letrozole 、 Breast cancer 、 Oncology 、 Internal medicine

摘要: Background Postmenopausal women with breast cancer (BC) receiving aromatase inhibitors are at increased risk for bone loss. The current study was undertaken to determine whether upfront versus delayed treatment zoledronic acid (ZA) impacted This report describes the 5-year follow-up results.

参考文章(19)

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. The Lancet. ,vol. 359, pp. 2131- 2139 ,(2002) , 10.1016/S0140-6736(02)09088-8

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer The New England Journal of Medicine. ,vol. 353, pp. 2747- 2757 ,(2005) , 10.1056/NEJMOA052258

Adam M. Brufsky, W. Graydon Harker, J. Thaddeus Beck, Linda Bosserman, Charles Vogel, Christopher Seidler, Lixian Jin, Ghulam Warsi, Eliza Argonza-Aviles, John Hohneker, Solveig G. Ericson, Edith A. Perez, Final 5-year results of Z-FAST trial: Adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole Cancer. ,vol. 118, pp. 1192- 1201 ,(2012) , 10.1002/CNCR.26313

D. Marshall, O. Johnell, H. Wedel, Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures BMJ. ,vol. 312, pp. 1254- 1259 ,(1996) , 10.1136/BMJ.312.7041.1254

Stephanie L. Hines, Betty Mincey, Todor Dentchev, Jeff A. Sloan, Edith A. Perez, David B. Johnson, Paul L. Schaefer, Steve Alberts, Heshan Liu, Stephen Kahanic, Miroslaw A. Mazurczak, Daniel A. Nikcevich, Charles L. Loprinzi, Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Research and Treatment. ,vol. 117, pp. 603- 609 ,(2009) , 10.1007/S10549-009-0332-2

Sydney Lou Bonnick, C. Conrad Johnston, Michael Kleerekoper, Robert Lindsay, Paul Miller, Louis Sherwood, Ethel Siris, Importance of Precision in Bone Density Measurements Journal of Clinical Densitometry. ,vol. 4, pp. 105- 110 ,(2001) , 10.1385/JCD:4:2:105

Antonis Valachis, Nikolaos P. Polyzos, Robert E. Coleman, Michael Gnant, Holger Eidtmann, Adam M. Brufsky, Rebecca Aft, Amye J. Tevaarwerk, Karen Swenson, Pehr Lind, Davide Mauri, Adjuvant Therapy With Zoledronic Acid in Patients With Breast Cancer: A Systematic Review and Meta-Analysis Oncologist. ,vol. 18, pp. 353- 361 ,(2013) , 10.1634/THEONCOLOGIST.2012-0261

Edith A. Perez, Robert G. Josse, Kathleen I. Pritchard, James N. Ingle, Silvana Martino, Brian P. Findlay, Tamara N. Shenkier, Richard G. Tozer, Michael J. Palmer, Lois E. Shepherd, Shifang Liu, Dongsheng Tu, Paul E. Goss, Effect of Letrozole Versus Placebo on Bone Mineral Density in Women With Primary Breast Cancer Completing 5 or More Years of Adjuvant Tamoxifen: A Companion Study to NCIC CTG MA.17 Journal of Clinical Oncology. ,vol. 24, pp. 3629- 3635 ,(2006) , 10.1200/JCO.2005.05.4882

Paul E. Goss, James N. Ingle, Silvana Martino, Nicholas J. Robert, Hyman B. Muss, Martine J. Piccart, Monica Castiglione, Dongsheng Tu, Lois E. Shepherd, Kathleen I. Pritchard, Robert B. Livingston, Nancy E. Davidson, Larry Norton, Edith A. Perez, Jeffrey S. Abrams, Patrick Therasse, Michael J. Palmer, Joseph L. Pater, A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer New England Journal of Medicine. ,vol. 349, pp. 1793- 1802 ,(2003) , 10.1056/NEJMOA032312

10.

Jack Cuzick, Ivana Sestak, Michael Baum, Aman Buzdar, Anthony Howell, Mitch Dowsett, John F Forbes, Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncology. ,vol. 11, pp. 1135- 1141 ,(2010) , 10.1016/S1470-2045(10)70257-6

5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.

来源期刊

我的账户

5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.

来源期刊

相似文章 10

我的账户